mossreports_fb_pixel

Moss Report on Lung Cancer, Small Cell

Alternative & Conventional Lung Cancer, Small Cell, Treatments (2019 Update)

We have separate Moss Reports on the two major forms of lung cancer:

Small Cell Lung Cancer (this page)

Non-Small Cell Lung Cancer (NSCLC)

Please be sure you order the one specific to the type of lung cancer you are dealing with.

The 2019 edition of the Moss Reports on small cell lung cancer (SCLC) has been completely revised and updated. It brings you a thorough and up-to-date discussion of the best results with surgery, radiation therapy, chemotherapy, immunotherapy, integrative, complementary and alternative treatments for lung cancer. But this is no dry medical text. This 500-page looseleaf book is written for patients in language that lay people can understand.

What’s New In Lung Cancer Treatment

 We also cover all aspects of lung cancer treatment, including such  complementary and alternative treatments as:

  • Cannabis
  • Vitamin C
  • Vitamin D
  • Turmeric and Curcumin
  • Coconut oil
  • Medicinal mushrooms
  • Melatonin
  • Acupuncture

We discuss the best supplements to take and even give Dr. Moss’s favorite brands. 

We keep our finger on the pulse of modern research. For instance, in 2019 we report on these latest developments in SCLC treatment:

  • Chemoradiation for SCLC
  • SCLC and Immune Checkpoint Blockade
  • Immunotherapy for Extensive-Stage SCLC
  • Nivolumab and EGFR or ALK Mutations

The 2019 updated Moss Reports on Small Cell Lung Cancer includes a discussion of how science is harnessing the immune system to fight these cancers. This includes very encouraging results with immune checkpoint inhibitors such as nivolumab (Opdivo). There is a discussion of which patients are likely to respond to this important new kind of treatment, and the role of cancer cell mutations in making this decision. We discuss the work of James P. Allison, PhD, winner of the 2018 Nobel Prize for his discovery of immune checkpoint inhibitors. Allison is proposing that these inhibitors be combined with certain anti-cancer viruses. But we show how this treatment is already being given at innovative European clinics.

Newly revised this year are the following topics and sections:

  • Dr. Moss’s Own Cancer Journey
  • Hospital Safety Grades
  • The Ultimate Guide to Cancer™: DIY Research
  • New Rules at FDA
  • Does Chemotherapy Destroy CTCs?
  • Anti-Cancer Herb Cardamom
  • Green Tea Is An Immune Checkpoint Inhibitor
  • Pomi-T Supplement
  • Vanillin Suppresses Cancer Stem Cells
  • Traditional Chinese Medicine
  • A Cautionary Note on Ketosis
  • Ketogenic Diet-Drug Synergy
  • Coffee for Prevention
  • Intravenous Vitamin C Scores a Big Victory
  • CBD Oil
  • “Deadly” Kratom and Cancer
  • Refreshing Exhausted Cancer-killing Cells
  • Rebellion Vs. High-Priced Drugs
  • Will Immune Inhibitors Work for You?
  • How to Increase Lymphocyte Count
  • Reolysin®
  • Aspirin and Cancer Deaths
  • Dichloroacetate (DCA)
  • Low-dose Combined Therapy
  • Dr. Kleef’s Response Statistics
  • Low-Dose Immune Drugs Are Effective
  • Rigvir Cell Line Study

Lung Cancer Treatment

Forty years ago, the treatment of lung cancer was among the simplest of all cancers. If the disease could be detected early the tumor could usually be surgically removed and the patient might therefore survive. The first article on the chemotherapy of small cell lung cancer did not appear until the 1970s! The chances of surviving five years then stood at just 12 percent.

So much has changed! By 2016, there were 1,750 articles appearing per year on the chemotherapy of lung cancer – around five every calendar day. Before the 1980s, almost nothing was known about the molecular biology of lung cancer. The first article on did not appear until 1987, when British scientists found a receptor that “may be a suitable target for therapy”.

Over 1,000 articles later, this marker is now routinely detected in many cases, and has become a standard target for several FDA-approved drugs. As a result, the treatment of lung cancer has gone from one of the simplest to one of the most complicated of all cancer types.

The emergence of a whole new class of immune-based drugs has led to a degree of optimism about the treatment of lung cancer that few of us anticipated a few decades ago.

No patient with small cell lung cancer (SCLC) or their loved ones should be without this outstanding Moss Report.

 

Moss Reports e-book Alternative Cancer Therapies

Moss Report
Lung Cancer, Small Cell
E-book

$349

Moss Report printed icon Alternative Cancer Therapies

Moss Report
Lung Cancer, Small Cell
Printed Book

$379

Discounts and Savings Available

Purchase both the E-Book and
Printed Moss Report and save $100.*

Purchase a Moss Report and
Schedule a Consultation and save $100.*

If you are a Medical Professional and refer patients to Moss Reports, click here find out more about our advocate program.

*Discounts applied when purchased together at check-out.

“I can’t tell you what a wealth of information we found and how helpful and informative the Report was. Thank you. My eyes were truly opened.” — L. C.

“Thanks for your help. Your service is a marvelous resource, tremendously helpful for those of us sifting through the masses of information that we have to go through in these really stressful situations.” — S. A.

Read many more testimonials on this page.

Table of Contents

  • A QUICK GUIDE TO CAM CANCER TREATMENTS
  • GREEN LIGHT TREATMENTS: WELL RESEARCHED APPROACHES
  • AMBER LIGHT TREATMENTS: EFFICACY AND SAFETY UNCLEAR
  • RED LIGHT TREATMENTS: POORLY RESEARCHED OR DANGEROUS
  • CONVENTIONAL TREATMENT SECTION
  • BASICS
  • ORIGIN OF CELLS
  • SYMPTOMS
  • CAUSES
  • DIAGNOSIS
  • PATHOLOGY
  • PARANEOPLASTIC SYNDROMES
  • PROGNOSIS
  • STAGING OF SCLC
  • LIMITED STAGE SCLC
  • EXTENSIVE STAGE SCLC
  • SURGERY
  • VATS SURGERY
  • RADIATION THERAPY
  • PROTON BEAM THERAPY (PBT)
  • STEREOTACTIC ABLATIVE RADIATION THERAPY (SABR)
  • PROPHYLACTIC CRANIAL IRRADIATION (PCI)
  • CHEMOTHERAPY
  • FDA-APPROVED DRUGS
  • NCCN RECOMMENDATIONS
  • 2017 UPDATE: SCLC AND IMMUNE CHECKPOINT BLOCKADE
  • 2017 UPDATE: NIVOLUMAB AND EGFR OR ALK MUTATIONS
  • EXPERIMENTAL TREATMENTS
  • ROSE BENGAL (PV-10®)
  • SOY AND LUNG CANCER RISK
  • CONCLUSIONS
  • TOP SUPPLEMENTS (THE SHORT LIST)
  • ANTI-CANCER PLAN ON A TIGHT BUDGET
  • ANTI-CANCER RECIPES
  • THE HALLMARKS OF CANCER
  • A NEW MODEL FOR CANCER TREATMENT
  • INNOVATIVE SURGERY
  • INNOVATIVE RADIATION THERAPY
  • INNOVATIVE CHEMOTHERAPY
  • NAUSEA AND VOMITING
  • ACUPUNCTURE
  • BETA-GLUCANS
  • HYPNOSIS
  • MUSIC
  • MOUTH SORES (STOMATITIS)
  • ZINC SULFATE
  • NERVE PAIN
  • HAIR LOSS
  • CRAMPS
  • PICKLE JUICE REMEDY
  • CHEMOSENSITIVITY TESTING
  • TARGETED THERAPIES
  • PRECISION MEDICINE INITIATIVE
  • ANTI-ANGIOGENESIS DRUGS
  • MOLECULAR AND GENOMIC TESTING
  • CIRCULATING TUMOR CELLS (CELLSEARCH)
  • MONOCLONAL ANTIBODIES
  • IMMUNE CHECKPOINT BLOCKADE (ICB)
  • CANCER STEM CELLS (CSCS)
  • DIETARY COMPOUNDS THAT KILL CANCER STEM CELLS (CSCS)
  • PHYSICAL ACTIVITY AND EXERCISE
  • FASTING AND THE KETOGENIC DIET
  • A COST-FREE WAY TO PREVENT CANCER RECURRENCES
  • CALORIC RESTRICTION
  • PRACTICAL NOTES ON FASTING
  • TOP TEN SUPPLEMENTS (THE EXPOSITION)
  • FOOD AND CANCER PREVENTION
  • VITAMINS, MINERALS & ANTIOXIDANTS
  • THE CONCURRENT USE DEBATE
  • RADIOPROTECTION
  • CONCURRENT USE OF ANTIOXIDANTS AND RADIATION
  • HERBS, SPICES AND BOTANICALS
  • HYPERTHERMIA
  • CRYOABLATION
  • SOUND, LIGHT AND ELECTRICITY
  • CANCER IMMUNOTHERAPY
  • VIRAL THERAPY (ONCOLYTIC VIRUSES)
  • ELECTROACUPUNCTURE
  • DRUGS NEW AND OLD
  • INNOVATIVE CANCER CLINICS
  • FINDING AN INTEGRATIVE PHYSICIAN
  • INTEGRATIVE ONCOLOGY DEPARTMENTS
  • AMERICAN CLINICS
  • INTERNATIONAL CLINICSSUPPLEMENTS AND SURGERY
  • CAM AND FATIGUE
  • POPULAR BUT UNLIKELY TREATMENTS

You may also be interested in…

Phone Consultation
with Ralph W. Moss, PhD

moss reports newsletter logo

Subscribe To Our Newsletter

Stay up to date with the latest from Moss Reports.

Newsletter Group

You have Successfully Subscribed!